Godina, Christopher
Tryggvadottir, Helga
Bosch, Ana
Borgquist, Signe
Belting, Mattias
Isaksson, Karolin
Jernström, Helena http://orcid.org/0000-0002-2301-5147
Funding for this research was provided by:
Cancerfonden (CAN 20 0763)
Medicinska Fakulteten, Lunds Universitet
Region Skåne (ALF 40620)
Region Skåne (ST-ALF, Yngre ALF)
Skånes universitetssjukhus
Fru Berta Kamprads Stiftelse
Lund University
Article History
Received: 28 November 2022
Accepted: 18 March 2023
First Online: 5 April 2023
Declarations
:
: Ana Bosch has received institutional honoraria from Pfizer, Roche, and Lilly for consultation and lectures. She has participated in Advisory Board meetings for Pfizer and Novartis. Co-founder and chair of the board for SACRA therapeutics. The other authors declare no conflict of interest.